Biogen (NASDAQ:BIIB) Releases FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 12.000-13.000 for the period, compared to the consensus EPS estimate of 13.450. The company issued revenue guidance of -, compared to the consensus revenue estimate of $10.1 billion.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Mizuho dropped their target price on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating for the company in a research report on Monday, June 15th. Needham & Company LLC lifted their price objective on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group boosted their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Piper Sandler restated an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. Finally, The Goldman Sachs Group raised their target price on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $221.11.

Biogen Price Performance

Shares of NASDAQ BIIB traded up $4.27 during mid-day trading on Wednesday, hitting $209.88. 1,070,645 shares of the stock traded hands, compared to its average volume of 1,287,446. The firm has a 50 day simple moving average of $200.25 and a two-hundred day simple moving average of $190.21. Biogen has a twelve month low of $124.56 and a twelve month high of $219.72. The company has a market cap of $30.99 billion, a PE ratio of 22.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the business earned $5.47 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts forecast that Biogen will post 11.28 EPS for the current fiscal year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Adjusted earnings were $3.60 per share versus the $3.04 Zacks consensus, while revenue reached approximately $2.74 billion, above the $2.46 billion estimate. Revenue increased 3.4% year over year. Biogen Inc. Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Growth portfolio momentum: Revenue from Biogen’s Growth Portfolio rose 24% to $1.06 billion, surpassing sales from its legacy multiple sclerosis portfolio. SKYCLARYS generated $168 million and ZURZUVAE generated $71 million, while products acquired through Apellis added SYFOVRE and EMPAVELI revenue after the May 14 closing. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Revenue outlook improved: Biogen now expects full-year 2026 revenue to grow at a mid-single-digit percentage rate compared with 2025, suggesting management sees continued strength in newer therapies.
• Positive Sentiment: Analyst target increased: Barclays raised its price target from $185 to $200, reflecting improved business execution, although it maintained an Equal Weight rating.
• Neutral Sentiment: Leqembi performance was mixed: Global second-quarter sales totaled ¥29.3 billion. The Alzheimer’s treatment contributed to the growth narrative but narrowly missed expectations, leaving investor focus on the pace of its commercial adoption.
• Negative Sentiment: Profitability weakened: Adjusted EPS declined from $5.47 a year earlier, while GAAP diluted EPS fell to $0.66 from $5.47 and net income dropped sharply to $97.5 million from $634.8 million.
• Negative Sentiment: EPS guidance is below expectations: Biogen issued full-year 2026 adjusted EPS guidance of $12 to $13, below the $13.45 consensus estimate. Legacy multiple sclerosis drug sales, including SPINRAZA revenue of $402 million, remain under pressure.

Institutional Trading of Biogen

A number of institutional investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. boosted its position in shares of Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 66 shares in the last quarter. Advisory Services Network LLC grew its position in shares of Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares during the period. CIBC Private Wealth Group LLC grew its position in shares of Biogen by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after buying an additional 89 shares during the period. QTR Family Wealth LLC increased its stake in shares of Biogen by 5.2% in the 4th quarter. QTR Family Wealth LLC now owns 1,852 shares of the biotechnology company’s stock valued at $350,000 after acquiring an additional 92 shares in the last quarter. Finally, Guardian Investment Management lifted its position in shares of Biogen by 1.9% during the 3rd quarter. Guardian Investment Management now owns 5,400 shares of the biotechnology company’s stock valued at $756,000 after acquiring an additional 100 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.